Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.33 |
| ▸ | BCL6 | P41182 | 2/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089499 | 0.93 | KIF11 (0.35) | KIF11MKNK1BCL6PTK2BBUB1 | |
| SCHEMBL30100704 | 0.93 | KIF11 (0.35) | KIF11MKNK1BCL6PTK2BBUB1 | |
| SCHEMBL26086897 | 0.86 | RHOA (0.40) | KIF11IRAK4TNIK | |
| SCHEMBL26088267 | 0.84 | GRM4 (0.43) | BCL6PTK2BBUB1GRM4KDR | |
| SCHEMBL26088918 | 0.84 | GRM4 (0.39) | KIF11BCL6PTK2BBUB1GRM4 | |
| SCHEMBL30100814 | 0.79 | KIF11 (0.35) | KIF11BCL6PTK2BPTK2TNIK | |
| SCHEMBL26088442 | 0.79 | KIF11 (0.35) | KIF11BCL6PTK2BPTK2TNIK | |
| SCHEMBL23674941 | 0.78 | RHOA (0.47) | KIF11IRAK4PTK2ULK1 | |
| SCHEMBL26086569 | 0.78 | EGFR (0.32) | KIF11GRM4TNIK | |
| SCHEMBL30100682 | 0.78 | BCL6 (0.38) | KIF11MKNK1BCL6PTK2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | KIF11 3560/4885MKNK1 1676/4885BCL6 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.